• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

接种 Ad26.RSV.preF/RSV preF 蛋白疫苗诱导的人类抗体 Fc 效应功能。

Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine.

机构信息

Ragon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.

Department of Biological Engineering, Massachusetts Institute of Technology , Cambridge, Massachusetts, USA.

出版信息

J Virol. 2023 Nov 30;97(11):e0077123. doi: 10.1128/jvi.00771-23. Epub 2023 Oct 30.

DOI:10.1128/jvi.00771-23
PMID:37902399
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10688327/
Abstract

Respiratory syncytial virus (RSV) can cause serious illness in older adults (i.e., those aged ≥60 years). Because options for RSV prophylaxis and treatment are limited, the prevention of RSV-mediated illness in older adults remains an important unmet medical need. Data from prior studies suggest that Fc-effector functions are important for protection against RSV infection. In this work, we show that the investigational Ad26.RSV.preF/RSV preF protein vaccine induced Fc-effector functional immune responses in adults aged ≥60 years who were enrolled in a phase 1/2a regimen selection study of Ad26.RSV.preF/RSV preF protein. These results demonstrate the breadth of the immune responses induced by the Ad26.RSV.preF/RSV preF protein vaccine.

摘要

呼吸道合胞病毒（RSV）可导致老年人（即年龄≥60 岁的人群）发生严重疾病。由于 RSV 预防和治疗的选择有限，因此预防老年人 RSV 介导的疾病仍然是一个重要的未满足的医疗需求。来自先前研究的数据表明，Fc 效应功能对于预防 RSV 感染很重要。在这项工作中，我们表明，在接受 Ad26.RSV.preF/RSV preF 蛋白疫苗的 1/2a 期方案选择研究中，≥60 岁的成年人中诱导了 Ad26.RSV.preF/RSV preF 蛋白的 Fc 效应功能免疫应答。这些结果证明了 Ad26.RSV.preF/RSV preF 蛋白疫苗诱导的免疫应答的广度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfee/10688327/24c6ee0fb6f5/jvi.00771-23.f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfee/10688327/cd4649db31b6/jvi.00771-23.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfee/10688327/f7e1da4d0dff/jvi.00771-23.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfee/10688327/5a06991bb1d5/jvi.00771-23.f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfee/10688327/e459140a0fee/jvi.00771-23.f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfee/10688327/37820219500f/jvi.00771-23.f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfee/10688327/24c6ee0fb6f5/jvi.00771-23.f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfee/10688327/cd4649db31b6/jvi.00771-23.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfee/10688327/f7e1da4d0dff/jvi.00771-23.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfee/10688327/5a06991bb1d5/jvi.00771-23.f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfee/10688327/e459140a0fee/jvi.00771-23.f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfee/10688327/37820219500f/jvi.00771-23.f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfee/10688327/24c6ee0fb6f5/jvi.00771-23.f006.jpg

相似文献

1
Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine.接种 Ad26.RSV.preF/RSV preF 蛋白疫苗诱导的人类抗体 Fc 效应功能。
J Virol. 2023 Nov 30;97(11):e0077123. doi: 10.1128/jvi.00771-23. Epub 2023 Oct 30.
2
Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.基于 Ad26.RSV.preF 的疫苗组合的安全性、免疫原性和方案选择：一项随机、双盲、安慰剂对照的 1/2a 期研究。
J Infect Dis. 2024 Jan 12;229(1):19-29. doi: 10.1093/infdis/jiad220.
3
Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.一项评估腺病毒 26 载体编码融合前 F （Ad26.RSV.preF）的呼吸道合胞病毒疫苗在 60 岁及以上成年人中的安全性和免疫原性的 1 期研究。
J Infect Dis. 2020 Aug 17;222(6):979-988. doi: 10.1093/infdis/jiaa193.
4
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF-Based Regimen in Japanese Adults Aged 60 Years and Older.一项评价 Ad26.RSV.preF 为基础的方案在 60 岁及以上日本成年人中进行单剂接种的安全性、反应原性和免疫原性的随机、双盲、安慰剂对照、1 期研究。
Influenza Other Respir Viruses. 2024 Jun;18(6):e13336. doi: 10.1111/irv.13336.
5
Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.单次接种 Ad26.RSV.preF 对健康成年人预防呼吸道合胞病毒感染的人体挑战研究。
J Infect Dis. 2022 Aug 26;226(3):396-406. doi: 10.1093/infdis/jiab003.
6
Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial.65 岁及以上成年人中 Ad26.RSV.preF/RSV preF 蛋白疫苗与高剂量流感疫苗同时接种：一项非劣效性试验。
J Infect Dis. 2024 Aug 16;230(2):e374-e383. doi: 10.1093/infdis/jiad594.
7
Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life.预测的中间和货架期末的 Ad26.RSV.preF/RSV preF 蛋白疫苗的免疫原性和安全性，作为整个货架期效力评估。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2344970. doi: 10.1080/21645515.2024.2344970. Epub 2024 May 23.
8
Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.在老年人中联合使用流感疫苗的 Ad26.RSV.preF 研究性疫苗的安全性和免疫原性。
J Infect Dis. 2021 Feb 24;223(4):699-708. doi: 10.1093/infdis/jiaa409.
9
Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.Ad26.RSV.preF-RSV 预 F 蛋白疫苗在老年人中的疗效和安全性。
N Engl J Med. 2023 Feb 16;388(7):609-620. doi: 10.1056/NEJMoa2207566.
10
Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models.基于稳定的融合前 F 蛋白的腺病毒和亚单位 RSV 疫苗在临床前模型中的免疫原性和保护效力。
Vaccine. 2022 Feb 7;40(6):934-944. doi: 10.1016/j.vaccine.2021.12.043. Epub 2021 Dec 29.

引用本文的文献

1
Adenovectored RSV prefusion glycoprotein + soluble glycoprotein combination immunization establishes persistent opsonophagocytic antibody response through IgG3.腺病毒载体呼吸道合胞病毒预融合糖蛋白+可溶性糖蛋白联合免疫通过IgG3建立持续的调理吞噬抗体反应。
Front Immunol. 2025 Jul 22;16:1609779. doi: 10.3389/fimmu.2025.1609779. eCollection 2025.
2
Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development.预防儿童呼吸道合胞病毒感染：当前的被动免疫疗法与疫苗研发
Pathogens. 2025 Jan 21;14(2):104. doi: 10.3390/pathogens14020104.
3
Virus neutralization assays for human respiratory syncytial virus using airway organoids.

本文引用的文献

1
Cell entry and innate sensing shape adaptive immune responses to adenovirus-based vaccines.细胞进入和先天感应塑造了针对腺病毒疫苗的适应性免疫反应。
Curr Opin Immunol. 2023 Feb;80:102282. doi: 10.1016/j.coi.2023.102282. Epub 2023 Jan 28.
2
Risk Factors and Medical Resource Utilization of Respiratory Syncytial Virus, Human Metapneumovirus, and Influenza-Related Hospitalizations in Adults-A Global Study During the 2017-2019 Epidemic Seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study).成人呼吸道合胞病毒、人偏肺病毒及流感相关住院治疗的风险因素与医疗资源利用——2017 - 2019流行季的一项全球研究（住院急性呼吸道感染[HARTI]研究）
Open Forum Infect Dis. 2021 Oct 5;8(11):ofab491. doi: 10.1093/ofid/ofab491. eCollection 2021 Nov.
3
用人呼吸道合胞病毒气道类器官进行病毒中和测定。
Cell Mol Life Sci. 2024 Jun 17;81(1):267. doi: 10.1007/s00018-024-05307-y.
4
Efficacy of Respiratory Syncytial Virus Vaccination to Prevent Lower Respiratory Tract Illness in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.呼吸道合胞病毒疫苗预防老年人下呼吸道疾病的疗效：一项随机对照试验的系统评价和荟萃分析
Vaccines (Basel). 2024 May 5;12(5):500. doi: 10.3390/vaccines12050500.
Risk factors and medical resource utilization in US adults hospitalized with influenza or respiratory syncytial virus in the Hospitalized Acute Respiratory Tract Infection study.美国住院急性呼吸道感染研究中因流感或呼吸道合胞病毒住院的成年人的风险因素和医疗资源利用。
Influenza Other Respir Viruses. 2022 Sep;16(5):906-915. doi: 10.1111/irv.12994. Epub 2022 Apr 26.
4
Adult Memory T Cell Responses to the Respiratory Syncytial Virus Fusion Protein During a Single RSV Season (2018-2019).成人对呼吸道合胞病毒融合蛋白的记忆 T 细胞反应在一个 RSV 季节（2018-2019）。
Front Immunol. 2022 Mar 29;13:823652. doi: 10.3389/fimmu.2022.823652. eCollection 2022.
5
Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates.接种非人灵长类动物后，对上、下呼吸道对呼吸道合胞病毒的保护作用的相关性。
Cell Host Microbe. 2022 Jan 12;30(1):41-52.e5. doi: 10.1016/j.chom.2021.11.006. Epub 2021 Dec 7.
6
Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017-2020.2017 年至 2020 年住院成人呼吸道合胞病毒感染发生率。
Clin Infect Dis. 2022 Mar 23;74(6):1004-1011. doi: 10.1093/cid/ciab595.
7
Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population.针对老年人群的呼吸道合胞病毒疫苗的考量因素。
Vaccines (Basel). 2021 Jun 9;9(6):624. doi: 10.3390/vaccines9060624.
8
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.Ad26.COV2.S 疫苗对人类 SARS-CoV-2 变异株的免疫原性。
Nature. 2021 Aug;596(7871):268-272. doi: 10.1038/s41586-021-03681-2. Epub 2021 Jun 9.
9
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.COVID-19 用 Ad26.COV2.S 疫苗的免疫原性。
JAMA. 2021 Apr 20;325(15):1535-1544. doi: 10.1001/jama.2021.3645.
10
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.两种异源 HIV 疫苗方案在健康、未感染 HIV 的成年人中的安全性和免疫原性（TRAVERSE）：一项随机、平行分组、安慰剂对照、双盲、1/2a 期研究。
Lancet HIV. 2020 Oct;7(10):e688-e698. doi: 10.1016/S2352-3018(20)30229-0.